Molecular Templates has been granted a patent for PD-L1 binding molecules conjugated to a toxin, targeting PD-L1 positive tumor cells. The method involves administering the molecule to treat cancer in humans, specifically targeting PD-L1 expressing tumor cells. GlobalData’s report on Molecular Templates gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Molecular Templates Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Molecular Templates, Peptide pharmacophores was a key innovation area identified from patents. Molecular Templates's grant share as of April 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Pd-l1 binding molecule for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Molecular Templates Inc

A recently granted patent (Publication Number: US11918649B2) discloses a method for treating cancer in human subjects by administering a PD-L1 binding molecule containing a Shiga toxin effector polypeptide and a binding region that specifically targets the extracellular part of PD-L1. The binding region includes specific amino acid sequences in the heavy chain variable region (VH) and light chain variable region (VL) to ensure effective binding to PD-L1 expressing tumor cells. The method aims to provide a therapeutic benefit in various types of cancer characterized by high mutational burden and solid tumors, including bladder, breast, colon, gastrointestinal, glioma, head and neck, kidney, liver, lung, lymphoma, mesothelioma, myeloma, skin, and urothelial cancers, among others.

Furthermore, the patent claims encompass variations in the Shiga toxin effector polypeptide, VH, VL, and the inclusion of a CD8+ T-cell epitope to enhance the immune response against cancer cells. The method also covers cancers that are refractory to existing treatments like ipilimumab, nivolumab, pembrolizumab, and others, as well as metastatic cancers. The innovative approach of utilizing a PD-L1 binding molecule with specific structural components highlights a promising strategy for addressing the complexities of cancer treatment, potentially offering new avenues for therapeutic interventions in challenging cancer types.

To know more about GlobalData’s detailed insights on Molecular Templates, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies